Outcomes of previous Coulter funding and support include more than $2B raised in angel or venture capital by startups developing Coulter funded technologies or generated through sale of companies commercializing Coulter funded technologies.
Congratulations to the nine teams who have been selected to receive FY27 funding through U-M BME’s Coulter Translational Research Partnership Program.
Established with a $20M endowment in 2005, the U-M BME Coulter Translational Research Partnership Program supports research directed at promising technologies within research laboratories that are progressing towards commercial development and clinical practice. Outcomes of previous Coulter funding and support include the formation of 6 FDA approvals, 20 exits and over $2B raised in angel or venture capital by startups developing Coulter funded technologies or generated through sale of companies commercializing Coulter funded technologies.
“U-M BME is honored to help advance these important initiatives,” said Douglas Noll, Interim Chair and Ann and Robert H. Lurie Professor of Biomedical Engineering and Professor of Radiology. “On behalf of the Coulter Program’s Oversight Committee, I’m pleased to congratulate these engineering and clinical research teams on receiving support for their translational projects. The committee selected a strong, innovative group of teams spanning a range of biomedical engineering research areas, and we look forward to seeing the impact of their work in the year ahead.”
“The U-M BME Coulter Translational Research Program supports teams from the earliest proposal stages through funded project development, helping guide promising laboratory discoveries toward commercial advancement and follow-on investment,” said Thomas Marten, Managing Director of the Coulter Program in Biomedical Engineering. “As part of the Coulter process, we work closely with teams and engage with an extensive network of external advisors who comprise the Coulter Advisory Board, as we evaluate projects for funding and provide guidance on milestone development. The nine projects chosen for funding this year reflect the continued strength of the program and represent a diverse set of innovative technologies with potential paths forward as therapeutics or medical devices.”